{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ovarian+cancer+peptide+vaccine&page=2",
    "query": {
      "intervention": "ovarian cancer peptide vaccine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 44,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ovarian+cancer+peptide+vaccine&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ovarian+cancer+peptide+vaccine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T01:54:09.864Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00799110",
      "title": "Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Dendritic Cell/Tumor Fusion Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "imiquimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2008-05",
      "completion_date": "2025-09",
      "has_results": true,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-10-11T01:54:09.864Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00799110"
    },
    {
      "nct_id": "NCT03761914",
      "title": "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Ovarian Cancer",
        "Colorectal Cancer",
        "Triple-negative Breast Cancer",
        "Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "galinpepimut-S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide",
          "type": "OTHER"
        },
        {
          "name": "GM-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sellas Life Sciences Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2019-09-30",
      "completion_date": "2022-10-27",
      "has_results": true,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-10-11T01:54:09.864Z",
      "location_count": 12,
      "location_summary": "Santa Rosa, California • Whittier, California • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03761914"
    },
    {
      "nct_id": "NCT01386502",
      "title": "CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colon Cancer",
        "Pancreatic Cancer",
        "Sarcoma",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "p53: 264-272 peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CT-011",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2011-06-15",
      "completion_date": "2011-10-31",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-11T01:54:09.864Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01386502"
    },
    {
      "nct_id": "NCT02111941",
      "title": "Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Tumor",
        "Fallopian Tube Mucinous Neoplasm",
        "Fallopian Tube Serous Neoplasm",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mucinous Cystadenocarcinoma",
        "Ovarian Seromucinous Carcinoma",
        "Ovarian Serous Cystadenocarcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Primary Peritoneal Serous Adenocarcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Stage IIIC Fallopian Tube Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Primary Peritoneal Cancer",
        "Stage IV Fallopian Tube Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Primary Peritoneal Cancer",
        "Undifferentiated Fallopian Tube Carcinoma",
        "Undifferentiated Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2014-04-14",
      "completion_date": "2021-07-27",
      "has_results": false,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-10-11T01:54:09.864Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02111941"
    },
    {
      "nct_id": "NCT01095848",
      "title": "A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Breast Neoplasms",
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2010-03",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2015-12-15",
      "last_synced_at": "2026-10-11T01:54:09.864Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Buffalo, New York • Durham, North Carolina + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01095848"
    },
    {
      "nct_id": "NCT00020267",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Adult Soft Tissue Sarcoma",
        "Colorectal Cancer",
        "Bone Cancer",
        "Ovarian Sarcoma",
        "Melanoma",
        "Colon Cancer",
        "Rectal Cancer",
        "Breast Cancer",
        "Eye Cancer",
        "Uterine Sarcoma"
      ],
      "interventions": [
        {
          "name": "interleukin-2",
          "type": "DRUG"
        },
        {
          "name": "MAGE-12 peptide vaccine",
          "type": "DRUG"
        },
        {
          "name": "Montanide ISA-51",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-10-11T01:54:09.864Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00020267"
    },
    {
      "nct_id": "NCT02978222",
      "title": "Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platinum Sensitive Ovarian Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "FRα peptide plus Adjuvant (GM-CSF)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Adjuvant (GM-CSF) Alone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Marker Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2017-07-20",
      "completion_date": "2020-01-15",
      "has_results": true,
      "last_update_posted_date": "2022-12-15",
      "last_synced_at": "2026-10-11T01:54:09.864Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02978222"
    },
    {
      "nct_id": "NCT00005023",
      "title": "Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Lung Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "HER-2/neu peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "1999-03",
      "completion_date": "2001-01",
      "has_results": false,
      "last_update_posted_date": "2017-11-30",
      "last_synced_at": "2026-10-11T01:54:09.864Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005023"
    },
    {
      "nct_id": "NCT01606241",
      "title": "Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Breast Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Stage IIA Breast Cancer",
        "Stage IIA Fallopian Tube Cancer",
        "Stage IIA Ovarian Cancer",
        "Stage IIB Breast Cancer",
        "Stage IIB Fallopian Tube Cancer",
        "Stage IIB Ovarian Cancer",
        "Stage IIC Fallopian Tube Cancer",
        "Stage IIC Ovarian Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIA Fallopian Tube Cancer",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIA Primary Peritoneal Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIB Fallopian Tube Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIB Primary Peritoneal Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IIIC Fallopian Tube Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Primary Peritoneal Cancer",
        "Stage IV Fallopian Tube Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Multi-epitope Folate Receptor Alpha Peptide Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2012-07-24",
      "completion_date": "2018-03-09",
      "has_results": false,
      "last_update_posted_date": "2024-08-21",
      "last_synced_at": "2026-10-11T01:54:09.864Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01606241"
    },
    {
      "nct_id": "NCT00603460",
      "title": "DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "DCVax-L and T Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2012-01",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2017-05-02",
      "last_synced_at": "2026-10-11T01:54:09.864Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00603460"
    }
  ]
}